Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: A multiinstitutional comparison

Journal of Nuclear Medicine

Volumn 45, Issue 10, 2004, Pages 1725-1733

  Wessels, Barry W ^a   Bolch, Wesley E ^b   Bouchet, Lionel G ^c   Breitz, Hazel B ^d   DeNardo, Gerald L ^e   Meredith, Ruby F ^f   Stabin, Michael G ^g   Sgouros, George ^h  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c VARIAN MEDICAL SYSTEMS   (United States)

^d Poniard Pharmaceuticals Inc   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g VANDERBILT UNIVERSITY   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Bone marrow; Dosimetry; Radionuclide therapy

Indexed keywords

IODINE 131; RHENIUM 186; ANTIBODY; RADIOACTIVE IODINE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM;

ADULT; AGED; ARTICLE; BONE MARROW; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOSIMETRY; DRUG ABSORPTION; FEMALE; HUMAN; IMMUNOTHERAPY; ISOTOPE LABELING; MALE; METHODOLOGY; PRIORITY JOURNAL; ALGORITHM; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; ISOTOPE DILUTION ASSAY; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RADIATION DOSE; RADIOIMMUNOTHERAPY; RADIOMETRY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; STANDARD; UNITED STATES;

ADULT; AGED; ALGORITHMS; ANTIBODIES; BONE MARROW; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, CARDIOVASCULAR; RADIOIMMUNOTHERAPY; RADIOISOTOPE DILUTION TECHNIQUE; RADIOISOTOPES; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RHENIUM; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 16544379777     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Breitz HB, Fisher DR, Wessels BW. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody. J Nucl Med. 1998;39:1746-1751.
2. Juweid ME, Zhang CH, Blumenthal RD, et al. Prediction of hematologic toxicity after radioimmunotherapy with I-131-labeled anticarcinoembryonic antigen monoclonal antibodies. J Nucl Med. 1999;40:1609-1616.
3. Lui T, Meredith RF, Saleh MN, et al. Correlation of toxicity with treatment parameters for 131-I-CC49 radioimmunotherapy in three phase II clinical trials. Cancer Biother Radiopharm. 1997;12:79-87.
4. O'Donoghue JA, Baidoo N, Deland D, Welt S, Divgi CR, Sgouros G. Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy. Cancer Biother Radiopharm. 2002;17:435-443.
5. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunconj Radiopharm. 1990;3:213-233.
6. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689-694.
7. Sgouros G, Divigi CR, Scott AM, et al. Hematologic toxicity in radioimmunotherapy: an evaluation of different predictive measures [abstract]. J Nucl Med. 1996;37(suppl):43P-44P.
8. Wessels BW, Breitz HB, Meredith R, et al. Bone marrow dosimetry model adjustments based on age, gender, and prior therapy [abstract]. J Nucl Med. 2000;41(suppl):83P.
9. 90Y-antibody therapy. J Nucl Med. 2002;43:1245-1253.
10. Siegel JA, Yeldell D, Goldenberg DM, et al. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med. 2003;44:67-76.
11. Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med. 1999;40:2102-2106.
12. Hindorf C, Linden O, Tennvall J, Wingradh K, Strand SE. Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetry. Cancer. 2002;94(suppl):1235-1239.
13. Snyder WS, Ford MR, Warner GG, Watson EE. 'S' Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs. MIRD Pamphlet No. 11, Revised. New York, NY: Society of Nuclear Medicine; 1975.
14. Siegel JA, Thomas SR, Stubbs JB, et al. MIRD Pamphlet No. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40(suppl):37S-61S.
15. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003;44:465-474.
16. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85:294-310.
17. Stabin MG, Siegel JA, Sparks RB. Sensitivity of model-based calculation S of red marrow dosimetry to changes in patient-specific parameters. Cancer Biother Radiopharm. 2002;17:535-543.
18. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
19. Stabin MG, Siegel JA, Sparks RB, Eckerman SK, Breitz HB. Contribution to red marrow absorbed dose from total body activity: a correction to the MIRD method. J Nucl Med. 2001;42:492-498.
20. Eckerman KF, Stabin MG. Dose conversion factors for marrow and bone by skeleton region [abstract]. J Nucl Med. 1994;35(suppl):112P.
21. Sgouros G, Stabin M, Edri Y, et al. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone or blood components. Med Phys. 2000;27:2150-2164.
22. Stabin MG, Eckerman KF, Bolch WE, Bouchet LG, Patton PW. Evolution and status of bone and marrow dose models. Cancer Biother Radiopharm. 2002;17:427-433.
23. Knox SJ, Meredith RF. Clinical radioimmunotherapy. Semin Radiat Oncol. 2000;10:73-93.
24. Zasadny KR, Wahl RL. A simplified method for determining therapeutic activity to administer for radioimmunotherapy [abstract]. J Nucl Med. 1996;37(suppl):43P.